Celecoxib, Function, Minimally Invasive Total Knee Arthroplasty, Pain Management
Conditions
Brief summary
This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day. This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.
Interventions
DRUGCelecoxib
Sponsors
Pfizer
Zimmer Biomet
St. Louis Joint Replacement Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* having undergone a minimally invasive total knee by select surgeon * voluntarily enrolled * independent community ambulators * only patients being discharged directly home
Exclusion criteria
* celecoxib allergy or intolerence * Renal insufficiency (defined as serum creatine level \>1.5 mg/dL or BUN level \>22mg/dL * History of bleeding gastic or duodenal ulceration * New York Heart Association Class III or IV Congestive Heart Failure * Previous myocardial infarction or cerebralvascular event * Severe inflammatory bowel disease * Known coagulation abnormality or hepatic disease * Chronic coumadin administration * Refusal by primary or cardiac physician
Countries
United States
Outcome results
None listed